Recent corporate updates for Lineage Cell Therapeutics focus on ongoing clinical developments across its pipeline of allogeneic cell therapies for conditions like spinal cord injury and dry age-related macular degeneration. Management continues to report disciplined cash-burn metrics, strategic maintenance of its operational runway, and regulatory updates regarding collaborative partnerships advancing its proprietary cell manufacturing technology.